Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Inclusion Criteria: * Informed Consent form signed by the participant or the participant's legal representative; if the participant is under the age of majority but capable of providing assent, signed assent from the participant. * Participant (or caretaker) was willing to comply with all protocol requirements. * Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB. * Participants 6 months of age and older. * Participants had 1 target wound within a prespecified size range at study entry. * Target wound was at least 21 days or older. Exclusion Criteria: * Participants who did not meet all the entry criteria outlined in inclusion criteria. * Selected target wound had clinical evidence of local infection. * Use of any investigational drug within 30 days before enrollment. * Use of immunotherapy or cytotoxic chemotherapy within 60 days before enrollment. * Use of systemic or topical steroidal therapy within 30 days before enrollment (inhaled steroids and ophthalmic drops containing steroids were allowed). * Use of systemic antibiotics within 7 days before enrollment. * Current or former malignancy. * Arterial or venous disorder resulting in ulcerated wounds. * Diabetes mellitus. * Pregnancy or breastfeeding during the study (a urine pregnancy test was performed at screening for female participants of childbearing potential). * Females of childbearing potential who were not abstinent and not practicing a medically acceptable method of contraception. * Known…